Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group MA.34 (BIG 4-11 / APHINITY) -- A Randomized Multicentre, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer was centrally activated April 5, 2012.

http://www.ctg.queensu.ca/trials/breast/ma34/ma34.html